Q&A: Boyd Discusses How Fox Chase Plans to 'Operationalize' Personalized Medicine

Jeff Boyd, Fox Chase's chief scientific officer, shared with Pharmacogenomics Reporter the center's plans to leverage its biorepositories and Phase I clinical trial expertise to woo pharma companies and advance personalized cancer drugs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.